The 22q13 deletion syndrome is characterised by intellectual disability (ID), delayed or absent speech, autistic-like behaviour and minor, nonspecific dysmorphic features. The deletion of the SHANK3 gene is thought to be responsible for these features. In this study, the clinical data of 7 patients with the 22q13 deletion syndrome are presented, obtained by clinical genetic examination, direct behavioural observation and by interview of family members and/or caregivers, complemented by behavioural questionnaires. The specific focus was on behaviour, psychopathology and the level of functioning during life course in order to determine common features that might contribute to the delineation of the syndrome. Major findings were a high incidence of psychiatric disorders, more in particular bipolar disorder (BPD) and attention deficit hyperactivity disorder (ADHD), and a sudden deterioration after acute events, in addition to a progressive loss of skills over years. Therefore, a deletion of SHANK3 may result in a dysfunctional nervous system, more susceptible to developmental problems and psychiatric disorders on the one hand, less able to recuperate after psychiatric and somatic events, and more vulnerable to degeneration at long term on the other hand. These results are exploratory and need to be confirmed in a larger sample.

Keywords:
Behaviour, Bipolar disorder, Deletion 22q13, Life course, Phelan-McDermid, Psychiatric disorders, SHANK3
1.
American Psychiatric Association: Diagnostic and statistical manual of mental disorders, ed 4 (American Psychiatric Association, Washington 2001).
2.
Boeckers TM, Bockmann J, Kreutz MR, Gundelfinger ED: ProSAP/Shank proteins – a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease. J Neurochem 81:903–910 (2002).
3.
Bonaglia MC, Giorda R, Borgatti R, Felisari G, Gagliardi C, et al: Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. Am J Hum Genet 69:261–268 (2001).
4.
Bonaglia MC, Giorda R, Beri S, De Agostini C, Novara F, et al: Molecular mechanisms generating and stabilizing terminal 22q13 deletions in 44 subjects with Phelan/McDermid syndrome. PLoS Genet 7:e1002173 (2011).
5.
Cusmano-Ozog K, Manning MA, Hoyme HE: 22q13.3 deletion syndrome: a recognizable malformation syndrome associated with marked speech and language delay. Am J Med Genet Part C Semin Med Genet 145C:393–398 (2007).
6.
de Bildt A, Kraijer D: Vineland Adaptive Behavior Scales (Vineland-Z). (PITS, Leiden 2003).
7.
Einfeld SL, Tonge BJ: The Developmental Behavior Checklist: the development and validation of an instrument to assess behavioral and emotional disturbance in children and adolescents with mental retardation. J Autism Dev Disord 25:81–104 (1995).
8.
Havens JM, Visootsak J, Phelan MC, Graham JM: 22q13 deletion syndrome: an update and review for the primary pediatrician. Clin Pediatr 49:43–53 (2004).
9.
Kato T: Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 61:3–19 (2007).
10.
Kraijer D, de Bildt A: The PDD-MRS: an instrument for identification of autism spectrum disorders in persons with mental retardation. J Autism Dev Disord 35:499–513 (2005).
11.
Manning MA, Cassidy SB, Clericuzio C, Cherry AM, Schwartz S, et al: Terminal 22q deletion syndrome: a newly recognized cause of speech and language disability in the autism spectrum. Pediatrics 114:451–457 (2004).
12.
Menten B, Maas N, Thienpont B, Buysse K, Vandesompele J, et al: Emerging patterns of cryptic chromosomal imbalance in patients with idiopathic mental retardation and multiple congenital anomalies: a new series of 140 patients and review of published reports. J Med Genet 43:625–633 (2006).
13.
Phelan MC, Rogers RC, Saul RA, Stapleton GA, Sweet K, et al: 22q13 deletion syndrome. Am J Med Genet 101:91–99 (2001).
14.
Severinsen JE, Bjarkam CR, Kiaer-Larsen S, Olsen IM, Nielsen MM, et al: Evidence implicating BRD1 with brain development and susceptibility to both schizophrenia and bipolar affective disorder. Mol Psychiatry 11:1126–1138 (2006).
15.
Sovner R, Stone A, Fox C: Ring chromosome 22 and mood disorders. J Intellect Disabil Res 40:82–86 (1996).
16.
Verma R, Mukerji M, Grover D, B-Rao C, Das SK, et al: MLC1 gene is associated with schizophrenia and bipolar disorder in southern India. Biol Psychiatry 58:16–22 (2005).
17.
Youngstrom EA, Findling RL, Youngstrom JK, Calabrese JR: Toward an evidence-based assessment of pediatric bipolar disorder. J Clin Child Adolesc Psychol 34:433–448 (2005).
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.